Evidence map›Paper›PMID 25614169›Full record

ArticleThe European respiratory journal2015

The tolerability of linezolid in the treatment of nontuberculous mycobacterial disease.

Kevin L Winthrop, Jennifer H Ku, Theodore K Marras, David E Griffith, Charles L Daley, Kenneth N Olivier, Timothy R Aksamit, Cara D Varley, Katherine Mackey, D Rebecca Prevots

Registry-linked trialOpen access · bronzeAbstract readComparative StudyLetter
In one paragraph

Article in The European respiratory journal, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03672630 (Comparison of Two- Versus Three-antibiotic Therapy for Pulmonary Mycobacterium Avium Complex Disease), which is not on this map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
5.0field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03672630 phase2 / phase3completednot on this mapstarted 2019, after this paper: background citation

Comparison of Two- Versus Three-antibiotic Therapy for Pulmonary Mycobacterium Avium Complex Disease

TypeinterventionalSponsorKevin WinthropRan2019 to 2026Enrolled474ConditionsMycobacterium Avium Complex, Nontuberculous Mycobacterium InfectionArmsAzithromycin, Ethambutol, Rifampin
3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 70 citations in OpenAlex.

  1. Macrolide-resistantJournal of clinical tuberculosis and other mycobacterial diseases · 2026
    Review
  2. Article
  3. Review
  4. Article
  5. Microbiology spectrum · 2024
    Article
  6. Review
  7. Article
  8. Article
  9. Antimicrobial agents and chemotherapy · 2023
    Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Prolonged tedizolid use in cutaneous non-tuberculous mycobacterial infection.Journal of clinical tuberculosis and other mycobacterial diseases · 2021
    Article
  15. Approach to the diagnosis and treatment of non-tuberculous mycobacterial disease.Journal of clinical tuberculosis and other mycobacterial diseases · 2021
    Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Looking beyond Typical Treatments for Atypical Mycobacteria.Antibiotics (Basel, Switzerland) · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 6 institutions in 2 countries.

Kevin L WinthropDivisions of Infectious Diseases, Public Health and Preventive Medicine, Oregon Health and Science University, Portland, OR, USA Winthrop@ohsu.edu.
Jennifer H KuDivisions of Infectious Diseases, Public Health and Preventive Medicine, Oregon Health and Science University, Portland, OR, USA.
Theodore K MarrasUniversity of Toronto, Toronto, Canada.
David E GriffithUniversity of Texas at Tyler, Tyler, TX, USA.
Charles L DaleyNational Jewish Health, Denver, CO, USA.
Kenneth N OlivierNational Institute Allergy and Infectious Diseases, Bethesda, MD, USA.
Timothy R AksamitMayo Clinic, Rochester, MN, USA.
Cara D VarleyDivisions of Infectious Diseases, Public Health and Preventive Medicine, Oregon Health and Science University, Portland, OR, USA.
Katherine MackeyDivisions of Infectious Diseases, Public Health and Preventive Medicine, Oregon Health and Science University, Portland, OR, USA.
D Rebecca PrevotsNational Institute Allergy and Infectious Diseases, Bethesda, MD, USA.
Oregon Health & Science University · USNational Institute of Allergy and Infectious Diseases · USMayo Clinic in Arizona · USThe University of Texas at Tyler · USUniversity of Colorado Denver · USUniversity of Toronto · CA

Funding

Bronchiectasis and chronic airway infectionZIAHL006200 · NHLBI · NATIONAL HEART, LUNG, AND BLOOD INSTITUTE · PI FENNELLY, KEVIN · 2015 to 2025
$25.1M
Epidemiology of Mycobacterial InfectionsZIAAI001035 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI PREVOTS, D. REBECCA · 2009 to 2025
$11.6M
Intramural NIH HHS ZIA HL006200
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Drug ToleranceAdministration, OralAdolescentAdultAgedAged, 80 and overAnti-Bacterial AgentsChildChild, PreschoolCohort StudiesConfidence IntervalsDose-Response Relationship, DrugDrug Administration ScheduleFemaleFollow-Up StudiesHumansAnti-Bacterial AgentsLinezolid

Identifiers

PMID25614169
PMCPMC6660918
OpenAlexW1969803578

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.